» Articles » PMID: 11016309

Influence of Concomitant CABG and Urgent/emergent Status on Mitral Valve Replacement Surgery

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2000 Oct 4
PMID 11016309
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Outcomes and resource utilization of patients undergoing mitral valve replacement (MVR) with or without concomitant coronary artery bypass grafting (CABG) were reviewed.

Methods: Data for 1,844 patients undergoing isolated primary MVR at Emory University Hospitals between 1980 and 1997 were recorded prospectively in a computerized database.

Results: The four groups included patients undergoing elective MVR with (n = 360) or without CABG (n = 1332) and urgent/emergent MVR with (n = 66) or without CABG (n = 86). Length of stay was significantly higher in patients undergoing elective MVR with CABG (15 days) than in those without CABG (11 days) but was not significantly different in patients undergoing urgent/emergent MVR with CABG (17 days) than in those without CABG (19 days). In-hospital mortality was significantly higher for patients undergoing elective (14%) or urgent/emergent (41%) MVR with CABG than in those undergoing MVR without CABG (elective:6%; urgent/emergent:20%). The 19-year survival rate was 32% for patients undergoing elective MVR with CABG compared with 51% for those without CABG and 28% for patients undergoing urgent/emergent MVR with CABG compared with 46% for those without CABG. Multivariate correlates of long-term mortality included older age, concomitant CABG, and urgent/emergent status. Hospital costs were significantly higher for patients undergoing elective MVR with ($33,216) than for those without ($23,890) CABG. No significant difference in cost were noted between patients undergoing urgent/emergent MVR with ($40,535) and without ($31,981) CABG.

Conclusions: The addition of CABG or urgent/emergent status to patients undergoing MVR significantly increases morbidity, mortality, and costs. Careful scrutiny of the benefits versus resource utilization is required for patients undergoing high risk MVR.

Citing Articles

The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass.

Pan T, Tuoerxun T, Chen X, Yang C, Jiang C, Zhu Y Front Immunol. 2023; 14:1082830.

PMID: 36761773 PMC: 9902923. DOI: 10.3389/fimmu.2023.1082830.


Trend, predictors, and outcomes of combined mitral valve replacement and coronary artery bypass graft in patients with concomitant mitral valve and coronary artery disease: a National Inpatient Sample database analysis.

Ullah W, Gul S, Saleem S, Syed M, Khan M, Zahid S Eur Heart J Open. 2022; 2(1):oeac002.

PMID: 35919659 PMC: 9242072. DOI: 10.1093/ehjopen/oeac002.


Sex differences in risks of in-hospital and late outcomes after cardiac surgery: a nationwide population-based cohort study.

Chang F, Chen S, Chan Y, Lin C, Wu V, Cheng Y BMJ Open. 2022; 12(2):e058538.

PMID: 35110325 PMC: 8811586. DOI: 10.1136/bmjopen-2021-058538.


Minimally invasive surgery for valvular heart disease.

Cuadrado D, Leacche M, Byrne J Curr Treat Options Cardiovasc Med. 2012; 14(6):584-93.

PMID: 23054559 DOI: 10.1007/s11936-012-0211-8.


Does urgent or emergent status influence choice in mitral valve operations? An analysis of outcomes from the Virginia Cardiac Surgery Quality Initiative.

LaPar D, Hennessy S, Fonner E, Kern J, Kron I, Ailawadi G Ann Thorac Surg. 2010; 90(1):153-60.

PMID: 20609766 PMC: 3071614. DOI: 10.1016/j.athoracsur.2010.03.044.